The application of biological markers in the diagnosis and treatment of airway inflammation and remodeling

doi:10.3877/cma.j.issn.2095-655X.2017.03.018

Abstract

Abstract:

The airway inflammation and remodeling is the pathophysiological basis of many common chronic lung diseases.It is difficult that the single indicator fully reflects the level and prognosis airway inflammation and remodeling.Because it involves the interaction of a variety of inflammatory cells, cellular components and inflammatory mediators, which can result in the certain heterogeneity of pathophysiology and clinical manifestations.This review focuse don asthma, chronic obstructive pulmonary disease, pulmonary hypertension and discusses biomarkers that has been researched for their usefulness to phenotype chronic inflammatory lung diseases which cause remodeling of the lung′s architecture.The goal is to evaluate the airway inflammation and remodeling during the chronic lung disease and to provide more treatment options for reference.

Key words: Biological markers, Airway remodeling, Airway inflammation, Lung diseases

Kai Guo, Jianyuan Shi, Xueming Gu, Zhengyi Tang, Shaojun Yin. The application of biological markers in the diagnosis and treatment of airway inflammation and remodeling[J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(03): 213-215.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2017.03.018

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2017/V05/I03/213

References 26

[1]	Busse W,Corren J,Lanier BQ, et al.Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma[J]. J Allergy Clin Immunol, 2001, 108(2): 184-190.
[2]	Katz LE,Gleich GJ,Hartley BF, et al.Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma[J]. Ann Am Thorac Soc, 2014, 11(4): 531-536.
[3]	Parulekar AD,Atik MA,Hanania NA.Periostin：a novel biomarker of TH2-driven asthma[J]. Curr Opin Pulm Med, 2014, 20(1): 60-65.
[4]	Corren J,Lemanske RF,Hanania NA, et al.Lebrikizumab treatment in adults with asthma[J]. N Engl J Med, 2011, 365(12): 1088-1098.
[5]	Bunyavanich S,Schadt EE.Systems biology of asthma and allergic diseases：a multiscale approach[J]. J Allergy Clin Immunol, 2015, 135(1): 31-42.
[6]	Keskin O,Balaban S,Keskin M, et al. Relationship between exhaled leukotriene and 8-isoprostane levels and asthma severity, asthma control level and asthma control test score[J]. Allergol Immunopathol(Madr), 2014, 42(3): 191-197.
[7]	Basu S. Bioactive eicosanoids：role of prostaglandin F(2alpha)and F(2)-isoprostanes in inflammation and oxidative stress related pathology[J]. Mol Cells, 2010, 30(5): 383-391.
[8]	Fatani SH.Biomarkers of oxidative stress in acute and chronic bronchial asthma[J]. J Asthma, 2014, 51(6): 578-584.
[9]	Agustí A,Edwards LD,Rennard SI, et al.Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.Persistent systemic inflammation is associated with poor clinical outcomes in COPD：a novel phenotype[J]. PLoS One, 2012, 7(5): e37483.
[10]	Davidsen PK,Herbert JM,Antczak P, et al.A systems biology approach reveals a link between systemic cytokines and skeletal muscle energy metabolism in a rodent smoking model and human COPD[J]. Genome Med, 2014, 6(8): 59.
[11]	Donaldson A,Natanek SA,Lewis A, et al.Increased skeletal muscle-specific microRNA in the blood of patients with COPD[J]. Thorax, 2013, 68(12): 1140-1149.
[12]	Seimetz M,Parajuli N,Pichl A, et al.Inducible NOS inhibition reverses to bacco-smoke-induced emphysema and pulmonary hypertension in mice[J]. Cell, 2011, 147(2): 293-305.
[13]	Malhotra D,Thimmulappa RK,Mercado N, et al.Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients[J]. J Clin Invest, 2011, 121(11): 4289-4302.
[14]	Gamez AS,Gras D,Petit A, et al.Supplementing defect in club cell secretory protein attenuates airway inflammation in COPD[J]. Chest, 2015, 147(6): 1467-1476.
[15]	Lomas DA,Silverman EK,Edwards LD, et al.Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort[J]. Thorax, 2008, 63(12): 1058-1063.
[16]	Sand JM,Knox AJ,Lange P, et al.Accelerated extracellular matrix turnover during exacerbations of COPD[J]. Respir Res, 2015, 16(1): 69.
[17]	Liu X,Ma S,Liu S, et al.The ratio of free to bound desmosine and isodesmosine may reflect emphysematous changes in COPD[J]. Lung, 2015, 193(3): 329-334.
[18]	Ma S,Lin YY,He J, et al.Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation[J]. COPD, 2013, 10(4): 473-481.
[19]	Papakonstantinou E,Karakiulakis G,Batzios S, et al.Acute exacerbations of COPD are associated with significant activation of matrix metallo proteinase 9 irrespectively of airway obstruction, emphysema and infection[J]. Respir Res, 2015, 16(1): 78.
[20]	D’Armiento JM,Goldklang MP,Hardigan AA, et al.Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema[J]. PLoS One, 2013, 8(2): e56352.
[21]	Yeager ME,Nguyen CM,Belchenko DD, et al.Circulating fibrocytes are increased in children and young adults with pulmonary hypertension[J]. Eur Respir J, 2012, 39(1): 104-111.
[22]	Tamura Y,Ono T,Kuwana M, et al.Human pentraxin 3(PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension[J]. PLoS One, 2012, 7(9): e45834.
[23]	Santos M,Reis A,Goncalves F, et al.Adiponectin levels are elevated in patients with pulmonary arterial hypertension[J]. Clin Cardiol, 2014, 37(1): 21-25.
[24]	Rosenberg M,Meyer FJ,Gruenig E, et al. Osteopontin(OPN) improves risk stratification in pulmonary hypertension(PH) [J]. Int J Cardiol, 2012, 155(3): 504-505.
[25]	Wei L,Warburton RR,Preston IR, et al.Serotonylated fibronectin is elevated in pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302(12): 1273-1279.
[26]	杨志寅. 现代医学科学发展中的缺憾和思考[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 1-7.

Please choose a citation manager

Content to export